| XERIS BIOPHARMA HOLDINGS |
| USA |
| Gesundheit |
| US98422E1038 / A3C4ZC |
| 2B30 (Frankfurt) / XERS (NASDAQ) |
| FRA:2B30, ETR:2B30, 2B30:GR, NASDAQ:XERS |
| - |
| https://www.xerispharma.c.. |
|
Xeris Biopharma Holdings Inc. is a biopharmaceutical company focused on the development and commercialization of innovative solutions utilizing its proprietary technology platforms. The primary functi..
>Volltext.. |
| 859.53 Mio. EUR |
| 1000.81 Mio. EUR |
| 225.27 Mio. EUR |
| 18.99 Mio. EUR |
| -13.24 Mio. EUR |
| -0.09 EUR |
| 218.09 Mio. EUR |
| 77.53 Mio. EUR |
| 8.94 Mio. EUR |
| 0.79 |
| 34.78% |
| 76.49% |
| - |
| - |
| - |
| XERIS |
| 02.03.26 |
|